Introduction
============

Postoperative nausea and vomiting (PONV) which frequently occurs after general anesthesia needs prevention and treatment. Apart from unpleasant experience in patients, PONV carries multiple potential medical risks, such as gastric aspiration, wound dehiscence, and delayed discharge from post-anesthesia care units \[[@B1]\].

The etiologies of PONV after general anesthesia are complicated. Signals from variable areas in the central nervous system (visual, vestibular center, and chemoreceptor trigger zones) stimulate the emetic center. Afferents from the pharynx, gastrointestinal tract, and mediastinum also stimulate the emetic center \[[@B2]\].

Propofol has been reported to be an effective antiemetic at low doses in patients undergoing anticancer therapy \[[@B3]\] and surgery \[[@B4],[@B5],[@B6]\] in many articles, but the precise mechanism by which propofol works as an antiemetic is unclear \[[@B2]\]. In this study, we evaluated the preventive antiemetic efficacy of different doses of propofol administered 15 minutes before the end of surgery without delaying emergence in middle aged females undergoing laparoscopic gynecologic surgery and receiving opioid-based intravenous patient controlled analgesia (PCA).

Materials and Methods
=====================

After obtaining approval from the Institutional Review Board for our prospective, double-blind, randomized study, 107 healthy women underwent a laparoscopy-assisted vaginal hysterectomy under general anesthesia. Written informed consent to the study was obtained from each patient the day before surgery. All patients belonged to the American Society of Anesthesiologist I or II. Exclusion criteria included history of allergies to any study medications, gastrointestinal disease, insulin-dependent diabetes mellitus, administration of antiemetics or steroids 24 hours prior to surgery, cardiac diseases, neurological diseases, and impaired hepatic/renal function. No significant differences in demographic data were observed among individual subjects ([Table 1](#T1){ref-type="table"}).

Patients were randomly allocated to 3 groups using a computerized randomization table: those who received 0.5 mg/kg of propofol (propofol 0.5 group, n = 33), those who received 1.0 mg/kg of propofol (propofol 1.0 group, n = 34), and those who received normal saline (control group, n = 40). All patients were premedicated with diazepam (7 mg, oral) 1 hour before surgery. Upon arrival at the operating room, preoperative anxiety was evaluated by an anesthesiologist, who was blinded to the study groups, using a 4-point scale. For induction of anesthesia, intravenous propofol 2 mg/kg and intravenous rocuronium 0.8 mg/kg was administrated to facilitate intratracheal intubation. After induction, anesthesia was maintained with 1.0-3.0 vol% sevoflurane and 50% nitrous oxide in oxygen. Ventilation was mechanically controlled and adjusted to maintain an end-tidal CO~2~ concentration of 35-40 mmHg, and esophageal temperature was maintained at 36 ± 1℃ using a forced-air warming blanket during surgery. For appropriate muscle relaxation, vecuronium was administered as required.

Fifteen minutes before the end of surgery, patients received normal saline or propofol at 2 different doses, 0.5 mg/kg or 1 mg/kg with fentanyl (50 µg) in addition to being connected to a PCA. Injected drugs were prepared in identically shaped syringes covered with black transparent plastic by persons not involved in the study. The PCA regimen consisted of 1,050 µg of fentanyl and 150 mg of ketorolac (total volume including saline, 100 ml) and was programmed to a 2 ml/h basal infusion and 2 ml on demand with a 15 minutes lockout time. Sevoflurane was discontinued at the completion of surgery. Glycopyrrolate (0.04 mg) and pyridostigmine (15 mg) were administered intravenously to facilitate the reversal of muscle relaxation. The endotracheal tube was removed when the patient was spontaneously breathing and was able to open her eyes on command. Emergence time was defined as time from discontinuation of sevoflurane to extubation. After extubation, patients were transferred to the post-anesthesia care unit (PACU).

Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, and vomiting was defined as the forceful expulsion of gastric contents from the mouth \[[@B1]\]. For the evaluation of the severity of nausea and postoperative pain, a visual analog score (VAS) was used. Ramosetron (0.3 mg) was administered intravenously when a patient complained of persistent nausea (VAS for nausea \>5), developed vomiting (\>1 episode) or needed another rescue antiemetic in the PACU. Fentanyl (50 µg) was administered intravenously if a VAS for pain was \>5 or if a patient needed an additional rescue agent. To avoid delay in treatment of pain or PONV, there was a detailed description of rescue antiemetic or opioid at a preanesthetic visit. When patients satisfied the discharge criteria of the PACU, they were transferred to the ward, and the stay time in the PACU was recorded. To evaluate recovery from anesthesia, the aldrete recovery score was used. Oxygen saturation, consciousness, circulation, respiration, and motor activity were accessed in the 3 grading systems (0, 1, and 2) by the anesthesiology staff. The patients were discharged when a score of \>9 (total 10) was reached \[[@B7]\]. All PONV episodes were recorded through direct interviews by a single anesthesiologist who was blinded to patient groups or through patient complaint of PONV during the postoperative 0-2, 2-24, and 24-48 hours.

SPSS (version18.0) to analyze data (version 18.0), and Sigma-Stat 12.0 is used to decide sample size. Statistical analyses were performed using the Chi-square test and Fisher\'s exact test for categorical data and one-way ANOVA for continuous data. A P value of \< 0.05 was considered significant. A sample size of \>102 decided to have an 80% power (β = 0.20) of detecting a 28-30% reduction in PONV from basal incidence 40% (α = 0.05) on the basis of the preliminary study in Chi-square analysis. Values are expressed as means ± SD or number of patients (%).

Results
=======

No significant differences were observed in preoperative anxiety ([Table 1](#T1){ref-type="table"}), postoperative pain (VAS), or the rescue fentanyl dose ([Table 2](#T2){ref-type="table"}) between the 3 groups. Emergence time was slightly longer in the propofol 0.5 and propofol 1.0 groups in the control group, but no significant difference was observed PACU stay time.

The incidence of nausea for the first postoperative 2 hours after surgery was significantly lower in the propofol 0.5 and propofol 1.0 groups than in the control group (12.1 vs 14.7 vs 40.0%) ([Fig. 1](#F1){ref-type="fig"}). However, no significant differences were observed at 2-24 hours, 24-48 hours, or throughout the study period. It was impossible to compare the severity of nausea between the 3 groups because of low incidence of nausea in the propofol 0.5 and propofol 1.0 groups. No significant differences in the incidence of vomiting were observed throughout the study period.

The number of patients who received a rescue antiemetic was smaller during the first postoperative 2 hours (P = 0.026) in the propofol 0.5 and propofol 1.0 groups than in the control group, but tended to become higher during 2-24 hours (P = 0.095) and 24-48 hours (P = 0.053). No differences were observed in the number of patients who received a rescue antiemetic throughout the study period ([Table 3](#T3){ref-type="table"}, [Fig.1](#F1){ref-type="fig"}).

Discussion
==========

We demonstrated a significantly lower incidence of nausea and number of rescue antiemetics in the propofol 0.5 and propofol 1.0 groups than in the control group during the first postoperative 2 hours. There were no significant differences in propofol doses.

PONV may result in a long-term hospital stay and increased treatment costs and affect the satisfaction of patients who received anesthesia. Nevertheless, the etiologies of PONV after surgery under general anesthesia are complex and not fully understood. Apfel et al. \[[@B8]\] reported that female gender, prior history of motion sickness or PONV, non-smoker, and use of postoperative opioids are the most important predictors of PONV. Additionally, the incidence of nausea and vomiting is much higher in women undergoing gynecologic laparoscopic surgery than in those undergoing other surgical procedures (67 vs 20%) \[[@B1],[@B9],[@B10]\].

Propofol has been universally accepted as an anesthetic since its approval by the Food and Drug Administration and introduction into clinical practice in 1989 \[[@B11]\]. Although propofol was initially accepted as an induction and maintenance hypnotic agent, its clinical use has remarkably expanded over the past 30 years. In this study, we focused on unique antiemetic properties of propofol. The mechanisms of antiemetic effects are not completely elucidated. Many investigators have conducted a variety of studies to identify the mechanism. Ostman et al. \[[@B12]\] found that the antiemetic effect of propofol is not attributed to lipid emulsion used to solubilize the drug. Borgeat et al. \[[@B4]\] reported that propofol does not have vagolytic properties. In a study by Hammas et al. \[[@B13]\], propofol reduces the intensity of retching after oral intake of ipecacuanha syrup, which releases 5-hydroxytryptamine. It is concluded that propofol may have a serotonin antagonistic effect. Propofol decreased synaptic transmission in the olfactory cortex in an animal study, suggesting a decrease in the release of excitatory amino acids such as glutamate and aspartate, which may be related to its antiemetic activity \[[@B14]\].

Numerous studies have identified appropriate dosages for the antiemetic effect of propofol. Borgeat et al. \[[@B3]\] used a 17 µg/kg/min propofol infusion in a group of patients receiving cisplatinum chemotherapy. Schulman et al. \[[@B15]\] indicated that the plasma concentration of propofol to treat refractory PONV is 197 ng/ml. Because this is a case report, further studies are needed for generalization. Borgeat at al. \[[@B4]\] administered a bolus of propofol (10-20 mg) for the treatment of PONV in the recovery room. However, pain on injection of propofol may be uncomfortable to an awakening patient. Erdem et al. \[[@B5]\] reported that intraoperative infusion of 20 µg/kg/min of propofol had a prophylactic antiemetic effect. Another study showed that 1.0 mg/kg of propofol at the end of surgery reduced both PONV and emergence agitation in children \[[@B6]\]. On the other hand, Kim et al. \[[@B16]\] reported that 0.5 mg/kg of propofol combined with dexamethasone was not effective in the prevention of PONV in pediatric patients with moyamoya disease.

Because our patients underwent relatively long duration surgery and received opioid-based PCA, we chose higher doses of propofol compared to those of previous studies and extended observation period until 48 hours postoperatively. In our study, propofol decreased the development of nausea during the first postoperative 2 hours, but had no effect at 2-24 hours, 24-48 hours, or throughout the study period, which may be related to pharmacokinetics of propofol. After an initial bolus of propofol, plasma levels decline rapidly as a result of redistribution and elimination. The initial distribution half-life of propofol is 2-8 minutes, and the clearance rate is 20-30 ml/kg/min \[[@B17]\]. Due to these properties, the plasma concentration of propofol may have diminished after 2 hours. This means that a single administration of propofol at the end of surgery could be not effective in patients receiving the opioid-based PCA. While intraoperative subhypnotic propofol infusion was effective during 24 hours postoperatively in patients without opioid-based PCA \[[@B5]\], total intravenous anesthesia with propofol was effective only during 6 hours postoperatively in patients with PCA \[[@B18]\]. For these patients, another treatment for PONV was needed. Propofol therapy is considered more useful for patients undergoing minor surgery, such as the outpatient-based laparoscopic procedure and tonsillectomy. However, exact propofol concentration having an antiemetic effect is still unknown \[[@B19]\]. Considering that various doses of propofol have been studied for the prevention of PONV, further studies on plasma concentration with antiemetic effect is required to solve this issue.

Interestingly, no significant differences were observed in the incidence of vomiting during the same period (P = 0.373). As our study protocol allowed the administration of ramosetron to patients who felt nauseous (VAS \> 5), the amount of ramosetron administered was higher in the control group than in the propofol 0.5 and propofol 1.0 groups (P = 0.026). The administration of ramosetron in patients who developed nausea may have depressed the development of vomiting and have blunted the differences between the 3 groups.

In contrast to the previous study \[[@B16]\], there was the prolongation of emergence time in the propofol 0.5 and propofol 1.0 groups compared to the control group (P \< 0.05). However, prolonged time was only 2.6-3.4 minutes, and it may not be significant in clinical practice.

In addition, this study did not compare the antiemetic effects of propofol with those of other drugs. Traditionally, dexamethasone, serotonin receptor antagonists, or several other drugs have been used to prevent and treat PONV \[[@B2]\]. Further investigations are required to evaluate the efficacy of propofol. Also, studies on synergistic or additional effects with other drugs are needed especially in high-risk patients.

In conclusion, administration of 0.5 mg/kg and 1.0 mg/kg of propofol at the end of surgery may effectively reduce the incidence of PONV with slight prolongation of emergence time within the first postoperative 2 hours in highly susceptible women undergoing laparoscopy-assisted vaginal hysterectomy and receiving opioid-based PCA.

![The incidence of nausea and the number of rescue antiemetics are significantly lower in the propofol 0.5 and propofol 1.0 groups than in the control group during postoperative 2 hours. ^\*^P \< 0.05 compared to the control group.](kjae-66-210-g001){#F1}
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Patient Demographics
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Values are means ± SD or number of patients. PONV: postoperative nausea and vomiting. There were no significant differences between the 3 groups.
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Postoperative Pain Scores and Emergence Time
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Values are means ± SD. VAS: visual analog score for pain evaluation. ^\*^Indicates P \< 0.05 compared to the control group: the propofol 0.5 group (P = 0.038) and the propofol 1.0 group (P = 0.006).
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Incidences of PONV and Anti-emetic Rescue
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Values are number of patients. ^\*^Indicates P \< 0.05 between the 3 groups.
